TITLE

Triple-combination rilpivirine, emtricitabine, and tenofovir (Complera/Eviplera) in the treatment of HIV infection

AUTHOR(S)
Bernardini, Claudia; Maggiolo, Franco
PUB. DATE
June 2013
SOURCE
Patient Preference & Adherence;2013, Vol. 7, p531
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The combination rilpivirine (RPV)/emtricitabine (FTC)/tenofovir (TDF) is a oncedaily, single-tablet regimen (STR) containing one nonnucleoside reverse-transcriptase inhibitor associated with two nucleos(t)ide reverse transcriptase inhibitors. It is approved by regulatory agencies (eg, US Food and Drug Association, European Medicines Agency) in all countries in which it is manufactured, except Switzerland, as first-line highly active antiretroviral therapy (HAART) for the treatment of naïve patients with HIV infection and a viral load HIV-RNA level of ⩽100,000 copies/mL. Two large trials (ECHO and THRIVE) comparing RPV with efavirenz, along with different background regimens, led to approval of the drug, while a more recent trial (STaR) explored the use of STR. RPV showed noninferiority to efavirenz in all the studies, including superiority as an STR in patients with HIV-RNA ⩽100,000 copies/mL in the STaR study. A positive CD4 cell response was observed in all the studies, both in the RPV and efavirenz groups. The incidence of virologic failures was higher for RPV, but was mostly referred to patients with HIV-RNA ⩽100,000 copies/mL. There were fewer adverse events (AEs) with the RPV-based regimens versus efavirenz-based regimens, with a lower discontinuation rate because of AEs, especially psychiatric-neurological AEs, and a significantly lower rate of bloodlipid abnormalities. In the SPIRIT study (a switch study), significantly greater improvements from baseline in serum total cholesterol, low-density lipoprotein cholesterol, and trygliceride were demonstrated in patients switching to RPV/FTC/TDF from a ritonavir-boosted protease inhibitor (PI/r)-based regimen, than in those who continued treatment with a PI/r regimen. RPV's better tolerability, associated with its once-daily STR formulation, is key to improving patients' adherence and quality of life, which are among the most important factors affecting the therapeutic efficacy of an antiretroviral regimen. In summary, RPV/FTC/TDF STR is a valuable treatment option for the majority of antiretroviral-naïve HIV-infected patients. Furthermore, the use of this STR in the therapeutic switch, like in the SPIRIT study, can result in another valuable option by which to reduce AEs and improve patients' quality of life.
ACCESSION #
89521570

 

Related Articles

  • Are All Subtypes Created Equal? The Effectiveness of Antiretroviral Therapy against Non-Subtype B HIV-1. Pond, Sergei L. Kosakovsky; Smith, Davey M. // Clinical Infectious Diseases;5/1/2009, Vol. 48 Issue 9, p1306 

    The article reports on the study regarding the effectiveness of modern combination of antiretroviral therapy against non-subtype B HIV-1 in the U.S. It states that the study examined the rates of viral suppression with antiretroviral therapy during infection with subtypes A, C, and D and with...

  • Retention in Opioid Substitution Treatment: A Major Predictor of Long-Term Virological Success for HIV-Infected Injection Drug Users Receiving Antiretroviral Treatment. Roux, Perrine; Carrieri, M. Patrizia; Cohen, Julien; Ravaux, Isabelle; Poizot-Martin, Isabelle; Dellamonica, Pierre; Spire, Bruno // Clinical Infectious Diseases;11/1/2009, Vol. 49 Issue 9, p1433 

    Background. The positive impact of opioid substitution treatment (OST) on opioid-dependent individuals with human immunodeficiency virus (HIV) infection is well documented, especially with regard to adherence to highly active antiretroviral therapy (HAART). We used the data from a 5-year...

  • Optimal timing for initiation of antiretroviral therapy: a prospective study on treatment naive HIV patients. Chakravarty, Jaya; Singh, Avinash; Singh, Anup; Rai, Madhukar; Gupta, Anoop; Agarwal, Amit; Sundar, Shyam // BMC Infectious Diseases;2012 Supplement, Vol. 12 Issue Supplment 1, p1 

    The article presents a prospective study on the optimal timing for initiation of antiretroviral therapy in naive HIV patients. The authors observed the immunological disease progression of patients for 1 year, which resulted to higher number of opportunistic infection in patients. They indicate...

  • Oral lesions among HIV seropositive individuals in an era of generic HAART: markers of HAART efficacy? Vasudevan, Janani; Sivasankar, Vaishnavi; Rao, Umadevi K.; Kumarasamy, Nagalingeswaran; Ranganathan, Kannan // BMC Infectious Diseases;2012 Supplement, Vol. 12 Issue Supplment 1, p1 

    The article presents a study on the prevalence of oral lesions among HIV seropositive individuals in India. The authors investigate the prevalence of oral lesions among HIV patients on Highly Active Antiretroviral Therapy (HAART). They state that patients under HAART have fewer orals lesions,...

  • Doubts about necessity and concerns about adverse effects: identifying the types of beliefs that are associated with non-adherence to HAART. Horne, Robert; Buick, Deanna; Fisher, Martin; Leake, Heather; Cooper, Vanessa; Weinman, John // International Journal of STD & AIDS;Jan2004, Vol. 15 Issue 1, p38 

    This cross-sectional study assessed beliefs about highly active antiretroviral therapy (HAART) and their association with reported adherence to HAART among 109 HIV-positive patients receiving HAART while attending an ambulatory care clinic in Brighton, UK. Patients' beliefs about the necessity...

  • The Evolution of Coreceptor Tropism in HIV-infected Patients Interrupting Suppressive Antiretroviral Therapy. Waters, Laura J.; Scourfield, Andrew T.; Marcano, Marie; Gazzard, Brian G.; Bower, Mark; Nelson, Mark; Stebbing, Justin // Clinical Infectious Diseases;3/1/2011, Vol. 52 Issue 5, p671 

    CCR5 antagonists may provide a well-tolerated switch option for patients experiencing tolerability or toxicity of their antiretroviral regimen. We analyzed stored samples from patients undergoing planned treatment interruptions for reasons other than virological failure, in order to analyze...

  • NIGELLA SATIVA CONCOCTION INDUCED SUSTAINED SEROREVERSION IN HIV PATIENT. Adekunle Onifade, Abdulfatah; Jewell, Andrew Paul; Adeola Adedeji, Waheed // African Journal of Traditional, Complementary & Alternative Medi;2013, Vol. 10 Issue 5, p332 

    Nigella sativa had been documented to possess many therapeutic functions in medicine but the least expected is sero-reversion in HIV infection which is very rare despite extensive therapy with highly active anti-retroviral therapy (HAART). This case presentation is to highlight the complete...

  • Pregnancy outcome in women infected with HIV-1 receiving combination antiretroviral therapy before versus after conception. Machado, E. S.; Hofer, C. B.; Costa, T. T.; Nogueira, S. A.; Oliveira, R. H.; Abreu, T. F.; Evangelista, L. A.; Farias, I. F. A.; Mercadante, R. T. C.; Garcia, M. F. L.; Neves, R. C.; Costa, V. M.; Lambert, J. S. // Sexually Transmitted Infections;Apr2009, Vol. 85 Issue 2, p82 

    Objective: The potential adverse effects of antiretroviral drugs during pregnancy are discrepant and few studies, mostly from Europe, have provided information about pregnancy outcomes of those already on treatment at conception. The aim of this study was to investigate the impact...

  • Penetration and Effectiveness of Antiretroviral Therapy in the Central Nervous System. Letendre, Scott; Ellis, Ronald J.; Best, Brookie; Bhatt, Archana; Marquie-Beck, Jennifer; LeBlanc, Shannon; Rossi, Steven; Capparelli, Edmund; McCutchan, J. Allen // Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry;Jun2009, Vol. 8 Issue 2, p169 

    Combination antiretroviral therapy (ART) has markedly reduced morbidity and mortality among HIV-infected individuals but not the prevalence of HIV-associated neurocognitive disorders (HAND). Several conditions may be responsible for the high prevalence of cognitive impairment, including...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics